Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-503-5p
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
PUMA
Cancer name
Colorectal Carcinoma
Cancer site
Colon, Rectum, and Anus
Treatment type
Chemotherapy
Drug
Oxaliplatin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Up
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma.
Tissue resource
human colorectal cancer and their corresponding non-tumorous colon samples
human colorectal cancer oxaliplatin-resistant cell lines HCT116-OxR
human colorectal cancer oxaliplatin-resistant cell lines HT29-OxR
human colorectal carcinoma cell lines HCT116
human colorectal carcinoma cell lines HT29
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Putuo Hospital, Shanghai University of Traditional Chinese Medicine
the Cell Bank of Chinese Academy of Science
Country
China
China
Continent
Asia
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.